Insmed Incorporated Announces Initiation of Phase II Clinical Trial with IPLEX(TM) in Myotonic Muscular Dystrophy

RICHMOND, VA., November 5 /CNW/ - Insmed Inc. (Nasdaq:INSM - News), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced the planned initiation of a 24-week, multi-center, randomized, double blind, placebo-controlled Phase II clinical trial with IPLEX(TM) in patients with Myotonic Muscular Dystrophy. The decision to initiate this trial is based on the promising results from an ongoing open-label, dose-escalation trial of IPLEX(TM) in this indication.

MORE ON THIS TOPIC